Despite advances in antiretroviral therapy that have revolutionized HIV disease
management, effective control of the HIV infection pandemic remains elusive. Beyond the …

Drug resistance is a common cause of treatment failure for HIV infection and cancer. The
high mutation rate of HIV leads to genetic heterogeneity among viral populations and …

Abstract Model-based analyses of natural selection often categorize sites into a relatively
small number of site classes. Forcing each site to belong to one of these classes places …

Background Contemporary antiretroviral therapies (ART) and management strategies have
diminished both human immunodeficiency virus (HIV) treatment failure and the acquired …

Abstract The European HIV Drug Resistance Guidelines Panel, established to make
recommendations to clinicians and virologists, felt that sufficient new information has …

Background. Low-level viremia (LLV; human immunodeficiency virus [HIV-1] RNA 50–999
copies/mL) occurs frequently in patients receiving antiretroviral therapy (ART), but there are …

Background Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to
impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy …

Objective: To assess the pharmacokinetics (PK), safety and efficacy of dolutegravir plus
optimized background regimen in HIV-infected treatment-experienced adolescents …

Accumulated empirical clinical experience, supported by animal or cell line models, has
initiated efforts of predicting synergistic combinatorial drugs with more-than-additive effect …

Objectives In low–middle-income countries, increasing levels of HIV drug resistance
(HIVDR) on second-line protease inhibitor (PI)-based regimens are a cause for concern …